Investing.com - bioAffinity Technologies (NASDAQ: BIAF) reported third quarter EPS of $-0.26, $0.11 worse than the analyst estimate of $-0.15. Revenue for the quarter came in at...
Investing.com - bioAffinity Technologies (NASDAQ: BIAF) reported second quarter EPS of $-0.20, $0.07 worse than the analyst estimate of $-0.13. Revenue for the quarter came in at...
Investing.com - bioAffinity Technologies (NASDAQ: BIAF) reported first quarter EPS of $-0.18, $0.03 better than the analyst estimate of $-0.21. Revenue for the quarter came in at...
Investing.com - bioAffinity Technologies (NASDAQ: BIAF) reported fourth quarter EPS of $-0.19, in line with the analyst estimate of $-0.19. Revenue for the quarter came in at $0.00...
Today's IPO for bioAffinity Technologies, Inc. (BIAF) opened for trading at $8.40 after pricing 1,282,600 units of securities at $6.125 per unit. Shares were halted shortly after...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today...
bioAffinity Technologies, Inc. (BIAF; BIAFW) today announced the publication of a paper titled “Porphyrin-modified beads for use as compensation controls in flow cytometry” in the...